The idea of using NSAIDs for the chemoprevention of melanoma comes from experimental and limited epidemiologic and clinical data suggesting that the extended use of NSAIDs decreases the risk of melanoma development. Ongoing larger epidemiologic studies looking in more detail at the strength of this association are expected to be released within the next year.
"Since multiple melanoma pathways have been identified, the effectiveness of a specific chemopreventive agent in a given high-risk population needs to be carefully thought out," Dr. Curiel-Lewandowski said.
Some have advanced this as an argument against chemoprevention.
SDEF and this newspaper are owned by Elsevier.